FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318539858> ?p ?o ?g. }

• W4318539858 endingPage "i724" @default.
• W4318539858 startingPage "i723" @default.
• W4318539858 abstract "Abstract Background Anti-tumour necrosis factor (anti-TNF) agents are associated with increased infection risk among elderly inflammatory bowel disease (IBD) patients and thus alternative biologics may be preferable. Previous cohort studies have demonstrated a superior safety profile for vedolizumab compared to anti-TNF agents in the elderly. However, there is limited comparative data on the safety and effectiveness of ustekinumab in elderly IBD patients. We aimed to compare the safety and effectiveness of ustekinumab and anti-TNF agents in elderly Crohn’s disease (CD) patients. Methods Patients ≥60 years old who commenced ustekinumab or an anti-TNF agent for CD were included in this multi-centre retrospective cohort study. The primary outcome was time to development of any infection. Secondary outcomes included incidence of serious infections, defined as requiring hospitalisation and effectiveness assessed by treatment persistence and clinical response rates. We appropriately adjusted for confounders using propensity score matched analysis weighted by the inverse predicted probability of treatment weighting and performed a logistic regression analysis to assess factors associated with infections and treatment persistence. Results 83 patients treated with ustekinumab and 124 patients (30 infliximab and 94 adalimumab) treated with anti-TNF therapy were included. A greater proportion of patients treated with ustekinumab were on concomitant steroids at baseline (37% vs 7.3%, p&lt;0.001). After propensity adjustment, the infection free survival at 12 months was comparable between ustekinumab and anti-TNF agents (HR 0.79, 95% CI 0.58-1.07, p=0.128). Serious infection rate for ustekinumab was 7.55/100 patient years and 5.30/100 for anti-TNFs (p=0.3). None of the variables including Charlson co-morbidity index were associated with infection risk in a multi-variable model. Unadjusted treatment persistence rates at 12 months were lower for ustekinumab compared to anti-TNF agents (68.1% vs 82.8% respectively, p=0.020). After propensity adjustment, there was no difference in treatment persistence at 6 months (OR 1.23, 95% CI 0.37-4.10, p=0.741) and 12 months (OR 1.07, 95% CI 0.45-2.55, p=0.9). There was a significant reduction in HBI at 6 and 12 months compared to baseline in both groups (p&lt;0.001). In a multivariable model, only concomitant thiopurine use was associated with treatment persistence at 12 months (OR 4.6, 95% CI 1.2-30.3, p=0.049). Conclusion We observed comparable safety and effectiveness in a propensity score adjusted comparison of ustekinumab and anti-TNF treated elderly CD patients. The rates of serious infections were comparable between the two groups." @default.
• W4318539858 created "2023-01-31" @default.
• W4318539858 creator A5016903463 @default.
• W4318539858 creator A5019174091 @default.
• W4318539858 creator A5039075244 @default.
• W4318539858 creator A5039114187 @default.
• W4318539858 creator A5043987428 @default.
• W4318539858 creator A5049892030 @default.
• W4318539858 creator A5059028472 @default.
• W4318539858 creator A5075017370 @default.
• W4318539858 creator A5089502195 @default.
• W4318539858 creator A5091288801 @default.
• W4318539858 date "2023-01-30" @default.
• W4318539858 modified "2023-10-04" @default.
• W4318539858 title "P596 Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort study" @default.
• W4318539858 doi "https://doi.org/10.1093/ecco-jcc/jjac190.0726" @default.
• W4318539858 hasPublicationYear "2023" @default.
• W4318539858 type Work @default.
• W4318539858 citedByCount "0" @default.
• W4318539858 crossrefType "journal-article" @default.
• W4318539858 hasAuthorship W4318539858A5016903463 @default.
• W4318539858 hasAuthorship W4318539858A5019174091 @default.
• W4318539858 hasAuthorship W4318539858A5039075244 @default.
• W4318539858 hasAuthorship W4318539858A5039114187 @default.
• W4318539858 hasAuthorship W4318539858A5043987428 @default.
• W4318539858 hasAuthorship W4318539858A5049892030 @default.
• W4318539858 hasAuthorship W4318539858A5059028472 @default.
• W4318539858 hasAuthorship W4318539858A5075017370 @default.
• W4318539858 hasAuthorship W4318539858A5089502195 @default.
• W4318539858 hasAuthorship W4318539858A5091288801 @default.
• W4318539858 hasBestOaLocation W43185398581 @default.
• W4318539858 hasConcept C126322002 @default.
• W4318539858 hasConcept C156957248 @default.
• W4318539858 hasConcept C167135981 @default.
• W4318539858 hasConcept C17923572 @default.
• W4318539858 hasConcept C201903717 @default.
• W4318539858 hasConcept C2776207728 @default.
• W4318539858 hasConcept C2777138892 @default.
• W4318539858 hasConcept C2778260677 @default.
• W4318539858 hasConcept C2778975655 @default.
• W4318539858 hasConcept C2779134260 @default.
• W4318539858 hasConcept C2779280984 @default.
• W4318539858 hasConcept C2780132546 @default.
• W4318539858 hasConcept C71924100 @default.
• W4318539858 hasConcept C72563966 @default.
• W4318539858 hasConceptScore W4318539858C126322002 @default.
• W4318539858 hasConceptScore W4318539858C156957248 @default.
• W4318539858 hasConceptScore W4318539858C167135981 @default.
• W4318539858 hasConceptScore W4318539858C17923572 @default.
• W4318539858 hasConceptScore W4318539858C201903717 @default.
• W4318539858 hasConceptScore W4318539858C2776207728 @default.
• W4318539858 hasConceptScore W4318539858C2777138892 @default.
• W4318539858 hasConceptScore W4318539858C2778260677 @default.
• W4318539858 hasConceptScore W4318539858C2778975655 @default.
• W4318539858 hasConceptScore W4318539858C2779134260 @default.
• W4318539858 hasConceptScore W4318539858C2779280984 @default.
• W4318539858 hasConceptScore W4318539858C2780132546 @default.
• W4318539858 hasConceptScore W4318539858C71924100 @default.
• W4318539858 hasConceptScore W4318539858C72563966 @default.
• W4318539858 hasIssue "Supplement_1" @default.
• W4318539858 hasLocation W43185398581 @default.
• W4318539858 hasOpenAccess W4318539858 @default.
• W4318539858 hasPrimaryLocation W43185398581 @default.
• W4318539858 hasRelatedWork W2326143279 @default.
• W4318539858 hasRelatedWork W2414272582 @default.
• W4318539858 hasRelatedWork W2984488335 @default.
• W4318539858 hasRelatedWork W2989681206 @default.
• W4318539858 hasRelatedWork W2999567714 @default.
• W4318539858 hasRelatedWork W3192675943 @default.
• W4318539858 hasRelatedWork W3201963472 @default.
• W4318539858 hasRelatedWork W4293719479 @default.
• W4318539858 hasRelatedWork W4353047497 @default.
• W4318539858 hasRelatedWork W4381125750 @default.
• W4318539858 hasVolume "17" @default.
• W4318539858 isParatext "false" @default.
• W4318539858 isRetracted "false" @default.
• W4318539858 workType "article" @default.